{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:35:48Z","timestamp":1777383348982,"version":"3.51.4"},"reference-count":51,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2013,2,14]],"date-time":"2013-02-14T00:00:00Z","timestamp":1360800000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0056083","type":"journal-article","created":{"date-parts":[[2013,2,14]],"date-time":"2013-02-14T22:02:33Z","timestamp":1360879353000},"page":"e56083","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":20,"title":["Targeting Heat Shock Protein 90 for the Treatment of Malignant Pheochromocytoma"],"prefix":"10.1371","volume":"8","author":[{"given":"Alessio","family":"Giubellino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carole","family":"Sourbier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brad","family":"Scroggins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Bullova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Landau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwen","family":"Ying","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Len","family":"Neckers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane B.","family":"Trepel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karel","family":"Pacak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2013,2,14]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(05)67139-5","article-title":"Phaeochromocytoma","volume":"366","author":"JW Lenders","year":"2005","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1055\/s-0031-1301302","article-title":"An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes","volume":"44","author":"AP Gimenez-Roqueplo","year":"2012","journal-title":"Horm Metab Res"},{"key":"ref3","first-page":"171","article-title":"Hereditary paraganglioma\/pheochromocytoma and inherited succinate dehydrogenase deficiency","volume":"63","author":"J Favier","year":"2005","journal-title":"Horm Res"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/sj.onc.1206300","article-title":"Novel succinate dehydrogenase subunit B (SDHB) mutations in familial phaeochromocytomas and paragangliomas, but an absence of somatic SDHB mutations in sporadic phaeochromocytomas","volume":"22","author":"DE Benn","year":"2003","journal-title":"Oncogene"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1055\/s-0032-1304594","article-title":"A decade (2001\u20132010) of genetic testing for pheochromocytoma and paraganglioma","volume":"44","author":"A Buffet","year":"2012","journal-title":"Horm Metab Res"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Weber A, Hoffmann MM, Neumann HP, Erlic Z (2012) Somatic Mutation Analysis of the SDHB, SDHC, SDHD, and RET Genes in the Clinical Assessment of Sporadic and Hereditary Pheochromocytoma. Horm Cancer.","DOI":"10.1007\/s12672-012-0113-y"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1210\/jc.2008-1972","article-title":"Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors","volume":"94","author":"C Jimenez","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s12022-012-9199-6","article-title":"Signaling pathways in pheochromocytomas and paragangliomas: prospects for future therapies","volume":"23","author":"S Nolting","year":"2012","journal-title":"Endocr Pathol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1055\/s-0029-1220687","article-title":"Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001)","volume":"41","author":"MR Druce","year":"2009","journal-title":"Horm Metab Res"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/nrm2918","article-title":"HSP90 at the hub of protein homeostasis: emerging mechanistic insights","volume":"11","author":"M Taipale","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrc2887","article-title":"Targeting the dynamic HSP90 complex in cancer","volume":"10","author":"J Trepel","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1210\/jc.2002-021299","article-title":"Expression profile of the telomeric complex discriminates between benign and malignant pheochromocytoma","volume":"88","author":"C Boltze","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4149\/endo_2011_02_65","article-title":"Phaeochromocytoma: a catecholamine and oxidative stress disorder","volume":"45","author":"K Pacak","year":"2011","journal-title":"Endocr Regul"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/107327481101800205","article-title":"Changing paradigms in the treatment of malignant pheochromocytoma","volume":"18","author":"RH Grogan","year":"2011","journal-title":"Cancer Control"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2174\/156802609789895728","article-title":"Update on Hsp90 inhibitors in clinical trial","volume":"9","author":"YS Kim","year":"2009","journal-title":"Curr Top Med Chem"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.bbamcr.2011.10.008","article-title":"Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers","volume":"1823","author":"K Jhaveri","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1016\/j.bmc.2008.10.087","article-title":"Discovery and development of heat shock protein 90 inhibitors","volume":"17","author":"T Taldone","year":"2009","journal-title":"Bioorg Med Chem"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1158\/1078-0432.CCR-11-1000","article-title":"Hsp90 molecular chaperone inhibitors: are we there yet?","volume":"18","author":"L Neckers","year":"2012","journal-title":"Clin Cancer Res"},{"key":"ref19","first-page":"1466","article-title":"STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer","volume":"11","author":"Y Wang","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1158\/1535-7163.MCT-11-0755","article-title":"Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy","volume":"11","author":"W Ying","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"e18552","DOI":"10.1371\/journal.pone.0018552","article-title":"Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK\/STAT signaling","volume":"6","author":"DA Proia","year":"2011","journal-title":"PLoS One"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.canlet.2011.10.019","article-title":"Characterization of two mouse models of metastatic pheochromocytoma using bioluminescence imaging","volume":"316","author":"A Giubellino","year":"2012","journal-title":"Cancer Lett"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s004410000290","article-title":"Pheochromocytoma cell lines from heterozygous neurofibromatosis knockout mice","volume":"302","author":"JF Powers","year":"2000","journal-title":"Cell Tissue Res"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s10585-009-9236-0","article-title":"Characterization of an animal model of aggressive metastatic pheochromocytoma linked to a specific gene signature","volume":"26","author":"L Martiniova","year":"2009","journal-title":"Clin Exp Metastasis"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1073\/pnas.73.7.2424","article-title":"Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor","volume":"73","author":"LA Greene","year":"1976","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"29936","DOI":"10.1074\/jbc.M204733200","article-title":"Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway","volume":"277","author":"JS Isaacs","year":"2002","journal-title":"J Biol Chem"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0092-8674(00)81588-3","article-title":"Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1","volume":"94","author":"J Zou","year":"1998","journal-title":"Cell"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1158\/1535-7163.MCT-05-0537","article-title":"Identification of new biomarkers for clinical trials of Hsp90 inhibitors","volume":"5","author":"H Zhang","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2007.11.7960","article-title":"Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study","volume":"25","author":"S Modi","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref30","first-page":"883","article-title":"Animal models of pheochromocytoma","volume":"19","author":"AS Tischler","year":"2004","journal-title":"Histol Histopathol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s12022-012-9195-x","article-title":"From transcriptional profiling to tumor biology in pheochromocytoma and paraganglioma","volume":"23","author":"A Cascon","year":"2012","journal-title":"Endocr Pathol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/nrc2502","article-title":"The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer","volume":"8","author":"WG Kaelin Jr","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1101\/gad.1648608","article-title":"The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor","volume":"22","author":"S Schlisio","year":"2008","journal-title":"Genes Dev"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s12022-011-9189-0","article-title":"Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma","volume":"23","author":"J Favier","year":"2012","journal-title":"Endocr Pathol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/00005537-200001000-00029","article-title":"Expression of angiogenic growth factors in paragangliomas","volume":"110","author":"RW Jyung","year":"2000","journal-title":"Laryngoscope"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000085171","article-title":"Vascular endothelial growth factor expression, vascularization and proliferation in paragangliomas","volume":"67","author":"J Brieger","year":"2005","journal-title":"ORL J Otorhinolaryngol Relat Spec"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/S0002-9440(10)64400-8","article-title":"Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors","volume":"161","author":"J Favier","year":"2002","journal-title":"Am J Pathol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1385\/EP:15:1:39","article-title":"The significance of angiogenesis in malignant pheochromocytomas","volume":"15","author":"PP Rooijens","year":"2004","journal-title":"Endocr Pathol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1210\/me.2010-0256","article-title":"Research resource: Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas","volume":"24","author":"E Lopez-Jimenez","year":"2010","journal-title":"Mol Endocrinol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.4161\/cc.7.8.5723","article-title":"HSP90: the Rosetta stone for cellular protein dynamics?","volume":"7","author":"DC Dezwaan","year":"2008","journal-title":"Cell Cycle"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nsmb0309-235","article-title":"Visualizing the twists and turns of a molecular chaperone","volume":"16","author":"L Neckers","year":"2009","journal-title":"Nat Struct Mol Biol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.tibs.2009.01.006","article-title":"The complex dance of the molecular chaperone Hsp90","volume":"34","author":"L Neckers","year":"2009","journal-title":"Trends Biochem Sci"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"24585","DOI":"10.1074\/jbc.270.41.24585","article-title":"Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association","volume":"270","author":"TW Schulte","year":"1995","journal-title":"J Biol Chem"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"39858","DOI":"10.1074\/jbc.M206322200","article-title":"Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function","volume":"277","author":"AD Basso","year":"2002","journal-title":"J Biol Chem"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.4161\/cc.6.15.4521","article-title":"ErbB-2 induces bilateral adrenal pheochromocytoma formation in mice","volume":"6","author":"EW Lai","year":"2007","journal-title":"Cell Cycle"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.gde.2008.01.004","article-title":"Acquired resistance to tyrosine kinase inhibitors during cancer therapy","volume":"18","author":"JA Engelman","year":"2008","journal-title":"Curr Opin Genet Dev"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2174\/156800907780809778","article-title":"Hsp90: a novel target for the disruption of multiple signaling cascades","volume":"7","author":"SC Bishop","year":"2007","journal-title":"Curr Cancer Drug Targets"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1158\/1078-0432.CCR-06-2966","article-title":"Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells","volume":"13","author":"W Xu","year":"2007","journal-title":"Clin Cancer Res"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1158\/1078-0432.CCR-08-0132","article-title":"Heat shock protein 90 as a drug target: some like it hot","volume":"15","author":"U Banerji","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"6831","DOI":"10.1158\/1078-0432.CCR-11-0821","article-title":"A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas","volume":"17","author":"A Rajan","year":"2011","journal-title":"Clin Cancer Res"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s12022-012-9194-y","article-title":"Murine models and cell lines for the investigation of pheochromocytoma: applications for future therapies?","volume":"23","author":"E Korpershoek","year":"2012","journal-title":"Endocr Pathol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0056083","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T19:22:00Z","timestamp":1562700120000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0056083"}},"subtitle":[],"editor":[{"given":"Vladislav V.","family":"Glinskii","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,2,14]]},"references-count":51,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2013,2,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0056083","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,14]]}}}